- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04869267
Acceptance and Commitment Therapy in Patients With Advanced Lung Cancer (ACT)
Effectiveness of Acceptance and Commitment Therapy on Fatigue Interference and Health-related Quality of Life Among Patients With Advanced Lung Cancer: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China
- Xiangya Hospital Central South University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged 18 or over;
- diagnosed with stage III or stage IV lung cancer by pathological section or cytology;
- experienced unexplained fatigue syndrome: the score of 3 or more on the Fatigue Symptom Inventory (FSI); and
- able to provide informed consent and effectively collect data.
Exclusion Criteria:
- diagnosed with cognitive dysfunction or other mental illnesses that may interfere with their completion of treatment;
- who are with a life expectancy <3 months, or whose physical conditions are considered ineligible for the present study based on the physician's judgment; and
- who are receiving or have just completed other lung cancer-related intervention programs within the last six months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ACT group
Participants in the intervention group will receive ACT intervention, consisting of four individual sessions (First session by face to face, the last three sessions by Wechat) of 60-90 min each (once/week), in addition to usual care.
|
Session 1: This session aims to let the participants get familiar with the interventionist. The interventionist will tell them the purpose of the program and basic rules. And the interventionist will promise their privacy protection. Session 2: This session includes how to separate thoughts/feelings/sensations related to diagnose with advanced lung cancer and experience of fatigue with facts and see these feelings in an objective way with observing self. Session 3: This session mainly aims to help participants understand the importance of values, differentiate values from goals and clarify their personal values. Session 4: This session aims at helping patients practice to engaging in committed action based on chosen values, motivated to change behavior in consistency with life direction and health goal. |
OTHER: Usual care group
Participants randomized to the control group will receive usual care, including treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge.
|
The usual care mainly includes treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the score of fatigue interference assessed by The Fatigue Symptom Inventory at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
A 13-item instrument that measures the intensity and interference of fatigue over the previous 7 days. The first four items are used to assess the intensity of fatigue, Item 5 - Item 11 are to assess the degree to which fatigue in the past week was judged to interfere with different aspects, such as general activity, bathe and dress ability, work activity, concentration ability, relation with others, enjoyment of life and mood, using a 11-point Likert scale ranging from 0 (no interference) to 10 (extreme interference). 0 indicates no fatigue and 127 indicates the worst fatigue intensity and interference. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of the score of fatigue interference assessed by The Fatigue Symptom Inventory at three months after the 4-week intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
A 13-item instrument that measures the intensity and interference of fatigue over the previous 7 days. The first four items are used to assess the intensity of fatigue, Item 5 - Item 11 are to assess the degree to which fatigue in the past week was judged to interfere with different aspects, such as general activity, bathe and dress ability, work activity, concentration ability, relation with others, enjoyment of life and mood, using a 11-point Likert scale ranging from 0 (no interference) to 10 (extreme interference). 0 indicates no fatigue and 127 indicates the worst fatigue intensity and interference. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of health-related quality of life assessed by Functional Assessment of Cancer Therapy - Lung, Version 4 at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
36 items scored from 0 (not at all) to 4 (very much) to assess QoL of lung cancer patients, including 5 domains: physical, social/family, emotional, and functional well-being, and additional concerns about lung cancer. The overall score can be obtained by adding all subscale scores. 0 indicates no quality of life and 144 indicates the highest quality of life. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of health-related quality of life assessed by Functional Assessment of Cancer Therapy - Lung, Version 4 at three months after the 4-week intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
36 items scored from 0 (not at all) to 4 (very much) to assess QoL of lung cancer patients, including 5 domains: physical, social/family, emotional, and functional well-being, and additional concerns about lung cancer. The overall score can be obtained by adding all subscale scores. 0 indicates no quality of life and 144 indicates the highest quality of life. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the score of cancer related fatigue assessed by The Multidimensional Fatigue Inventory at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
20-item self-reported instrument testing the subjective experience of fatigue. 20 indicates the low level of fatigue and 80 indicates the high level of fatigue. 20 indicates low level of fatigue and 80 indicates the high level of fatigue. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of cancer related fatigue assessed by The Multidimensional Fatigue Inventory at three months after the intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
20-item self-reported instrument testing the subjective experience of fatigue. 20 indicates the low level of fatigue and 80 indicates the high level of fatigue. 20 indicates low level of fatigue and 80 indicates the high level of fatigue. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of depressive symptoms assessed by The Patient Health Questionnaire (PHQ-9) at one week after the intervention.
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
A 9-item scale to measure the severity of depressive symptom ranged from 0 to 27, in which each item can be score from 0 (not at all) to 3 (nearly every day). 0 indicates no depression and 27 indicates severe depression. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of depressive symptoms assessed by The Patient Health Questionnaire (PHQ-9) at three months after the intervention.
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
A 9-item scale to measure the severity of depressive symptom ranged from 0 to 27, in which each item can be score from 0 (not at all) to 3 (nearly every day). 0 indicates no depression and 27 indicates severe depression. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of anxiety assessed by Generalized Anxiety Disorder Scale (GAD-7) at one week after the intervention.
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
A brief self-report instrument to measure severity of anxiety with 7 items ranged from 0 to 21. 0 indicates no anxiety and 21 indicates severe anxiety. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of anxiety assessed by Generalized Anxiety Disorder Scale (GAD-7) at three months after the intervention.
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
A brief self-report instrument to measure severity of anxiety with 7 items ranged from 0 to 21. 0 indicates no anxiety and 21 indicates severe anxiety. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of psychological distress assessed by Impact of Events Scale -Revised version at one week after the intervention.
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
It has 22 items containing three domains: Intrusion, Avoidance, and Hyperarousal subscales using a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely) ranged from 0 to 88. 0 indicates low level of distress and 88 indicates severe distress. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of psychological distress assessed by Impact of Events Scale -Revised version at three months after the intervention.
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
It has 22 items containing three domains: Intrusion, Avoidance, and Hyperarousal subscales using a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely) ranged from 0 to 88. 0 indicates low level of distress and 88 indicates severe distress. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in exercise capacity assessed by self-designed questions at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Including the type of exercise (What kind of exercise do you usually do?); the intensity of exercise (What intensity of exercise do you usually do?
Low/moderate/high?); frequency of exercise per week (How many times do you exercise on average a week?); and the duration of exercise each time (min) (How long will you take each exercise?)
Change= (One week after the intervention score - Baseline score)
|
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in exercise capacity assessed by self-designed questions at three months after the intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Including the type of exercise (What kind of exercise do you usually do?); the intensity of exercise (What intensity of exercise do you usually do?
Low/moderate/high?); frequency of exercise per week (How many times do you exercise on average a week?); and the duration of exercise each time (min) (How long will you take each exercise?)
Change= (Three months after the intervention score - Baseline score)
|
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of psychological flexibility assessed by Comprehensive assessment of Acceptance and Commitment Therapy processes at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
A comprehensive ACT process measure to evaluate the level of psychological flexibility (and constituent sub-process) within the ACT model with 18 items ranged from 18 to 90. 18 indicates low level of psychological flexibility and 90 indicates the high level of psychological flexibility. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of psychological flexibility assessed by Comprehensive assessment of Acceptance and Commitment Therapy processes at three months after the intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
A comprehensive ACT process measure to evaluate the level of psychological flexibility (and constituent sub-process) within the ACT model with 18 items ranged from 18 to 90. 18 indicates low level of psychological flexibility and 90 indicates the high level of psychological flexibility. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of acceptance assessed by Acceptance and Action Cancer Questionnaire at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
18-item questionnaire to measure experiential avoidance, in which participants response the possibility that they accept or avoid repulsive thoughts and feelings to each item using a 7-point Likert scale (1 = never true to 7 = always true) ranged from 18 to 126. The higher the overall score, the greater level of experiential avoidance or low level of acceptance. 18 indicates low level of acceptance and 90 indicates the high level of acceptance. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of acceptance assessed by Acceptance and Action Cancer Questionnaire at three months after the intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
18-item questionnaire to measure experiential avoidance, in which participants response the possibility that they accept or avoid repulsive thoughts and feelings to each item using a 7-point Likert scale (1 = never true to 7 = always true) ranged from 18 to 126. The higher the overall score, the greater level of experiential avoidance or low level of acceptance. 18 indicates low level of acceptance and 90 indicates the high level of acceptance. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Change from baseline in the score of cognitive fusion assessed by Cognitive Fusion Questionnaire at one week after the intervention
Time Frame: Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
An instrument to measure cognitive fusion, one of the components in the model of psychopathology of ACT. It has 9 items scored by 7-point Liker scale (1 = never true to 7 = always true) ranged from 9 to 63. 9 indicates low level of cognitive fusion and 63 indicates the high level of cognitive fusion. Change= (One week after the intervention score - Baseline score) |
Baseline (T0) and post-intervention (T1, one week after the 4-week intervention)
|
Change from baseline in the score of cognitive fusion assessed by Cognitive Fusion Questionnaire at three months after the intervention
Time Frame: Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
An instrument to measure cognitive fusion, one of the components in the model of psychopathology of ACT. It has 9 items scored by 7-point Liker scale (1 = never true to 7 = always true) ranged from 9 to 63. 9 indicates low level of cognitive fusion and 63 indicates the high level of cognitive fusion. Change= (Three months after the intervention score - Baseline score) |
Baseline (T0) and three months follow-up (T2, three months after the 4-week intervention)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Huiyuan LI, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CREC Ref. No. 2020.581
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Acceptance and Commitment Therapy (ACT)
-
Anne Roche, MACompletedQuality of Life | AgingUnited States
-
VA Office of Research and DevelopmentUniversity of Alabama, TuscaloosaRecruitingPsychological StressUnited States
-
Duke UniversityActive, not recruitingHematopoietic Steam Cell Transplantation (HCT)United States
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Plexiform NeurofibromasUnited States
-
Southern Methodist UniversityCompletedAnxiety | Nonsuicidal Self-InjuryUnited States
-
Rikard WicksellAFA Insurance; The Swedish Society of MedicineCompletedInflammation | Chronic Pain
-
King's College LondonDiabetes UKUnknownDiabetes Mellitus | Painful Diabetic NeuropathyUnited Kingdom
-
University of GlasgowNHS Greater Glasgow and ClydeCompletedSchizophrenia | Bipolar Disorder | Schizo-affective Disorder | PsychosisUnited Kingdom
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustRecruiting
-
University of Alabama at BirminghamWithdrawnDepression | Stroke | Stress | AnxietyUnited States